Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
William Conway
R., & Hagen, T
Data extraction Two designated authors (AM and SS) meticulously extracted pertinent data from the included studies, including authorship details, publication timeline, samples of the study, mean demographic parameters (e.g., age, sex, baseline weight, and baseline BMI), type of bariatric surgery, prevalent background diseases, type of the GLP-1RAs therapy, the time of the initiation of the medical treatment, laboratory indices, amount of weight-change, and a comprehensive array of outcome measures, such as nausea, vomiting, diarrhea, and serious adverse events
His hard work and commitment to clients establishes him as a leader in his field, with
By application analysis In 2024, the type 2 diabetes mellitus segment led the GLP-1 receptor agonist market due to the high incidence of the disease and the major efficacy of these drugs in controlling blood sugar levels and encouraging weight loss, contributing majorly to the expansion of the type 2 diabetes mellitus segment
US$ 20.80
US$ 21.46
US$ 26.84
US$ 27.09
US$ 21.49
